• LAST PRICE
    3.8300
  • TODAY'S CHANGE (%)
    Trending Down-0.0600 (-1.5424%)
  • Bid / Lots
    3.8300/ 2
  • Ask / Lots
    3.8500/ 5
  • Open / Previous Close
    3.8600 / 3.8900
  • Day Range
    Low 3.7897
    High 3.8750
  • 52 Week Range
    Low 0.9200
    High 5.8400
  • Volume
    38,285
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.89
TimeVolumeOMER
09:32 ET11183.875
09:36 ET4473.84
09:41 ET47623.8
09:45 ET5003.8101
09:48 ET10003.815
09:50 ET18343.87
09:59 ET12003.86
10:01 ET120913.83
10:03 ET9003.84
10:14 ET118153.83
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOMER
Omeros Corp
225.4M
-1.3x
---
United StatesTNYA
Tenaya Therapeutics Inc
224.2M
-1.7x
---
United StatesATAI
ATAI Life Sciences NV
226.0M
-5.6x
---
United StatesSLDB
Solid Biosciences Inc
222.6M
-1.4x
---
United StatesGOSS
Gossamer Bio Inc
228.5M
-0.9x
---
United StatesSKYE
Skye Bioscience Inc
221.2M
-1.7x
---
As of 2024-06-26

Company Information

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Contact Information

Headquarters
201 Elliott Avenue WestSEATTLE, WA, United States 98119
Phone
206-676-5000
Fax
206-676-5005

Executives

Chairman of the Board, President, Chief Executive Officer
Gregory Demopulos
Chief Accounting Officer, Vice President - Finance
Michael Jacobsen
Vice President - Science, Chief Scientific Officer
George Gaitanaris
Vice President, General Counsel, Secretary
Peter Cancelmo
Vice President - Human Resources
Peter Williams

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$225.4M
Revenue (TTM)
$0.00
Shares Outstanding
57.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.45
EPS
$-2.90
Book Value
$-0.41
P/E Ratio
-1.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.